CareDx to Participate in National Kidney Foundation 2021 Spring Clinical Meetings
04/05/2021 - 07:00 AM
CareDx to Host Virtual Exhibitor Showcase and Continuing Medical Education Program
SOUTH SAN FRANCISCO, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced its presence at the National Kidney Foundation’s 2021 Spring Clinical Meetings, which will take place virtually, April 6-10, 2021.
As a leader in non-invasive approaches for assessing the health of transplanted kidneys, CareDx will host “Next Generation Care for Kidney Transplant Patients,” a 30-minute exhibitor showcase on April 6th from 11:00-11:30 a.m. Eastern Time.
Innovations in Kidney Transplant Care , with Dr. Christopher Boshkos, Medical Director of Kidney Transplantation at CareDxAlloSure: Standard of Care for Kidney Transplant Surveillance , with Dr. Matthew Weir, Division Head of Nephrology at the University of Maryland School of Medicine“I’m looking forward to highlighting research from the RADAR study, where AlloSure differentiates ambiguous allograft rejection in borderline cases, and presenting select case studies to illustrate long-term patient follow up with AlloSure from the KOAR registry,” said Dr. Matthew Weir, Division Head of Nephrology at the University of Maryland School of Medicine.
In addition, CareDx is sponsoring the “Diagnosis of Acute Rejection in Kidney Transplantation: A Clinical Update,” a continuing medical education (CME) program on April 8th from 12:30–1:30 p.m. Eastern Time.
Program details:
Acute Rejection in Kidney Transplantation: Pathophysiology and Impact on Outcomes , presented by Tarek Alhamad, MD, MS, Medical Director of Transplant Nephrology at Washington University School of Medicine in St. LouisDiagnostic Modalities for Acute Rejection in Kidney , presented by Deirdre Sawinski, MD, Assistant Medical Director, Penn Kidney Pancreas Transplant ProgramAdvances in Non-Invasive Diagnosis of Acute Rejection in Kidney Transplantation , presented by Jonathan Bromberg, MD, PhD, Vice Chair for Research, University of Maryland School of Medicine “The NKF Spring Clinical Meetings are always a highlight for us,” said Dr. Sham Dholakia, SVP Medical Affairs, CareDx. “We are excited to showcase the latest in kidney transplant surveillance data at this great event.”
Additional information is available at https://www.kidney.org/spring-clinical
About CareDx www.CareDx.com
CONTACTS:
Investor Relationsinvestor@caredx.com
CDNA Rankings
#5231 Ranked by Stock Gains
CDNA Stock Data
Industry
Medical Laboratories
Sector
Health Care and Social Assistance
Tags
Health Technology, Medical Specialties, Health Care and Social Assistance, Medical Laboratories
Country
US
City
South San Francisco
About CDNA
caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos
